CVT-510: Phase II

In a U.S. open-label dose-escalation Phase II trial in 37 patients with paroxysmal supraventricular tachycardia (PSVT), a type of atrial arrhythmia, 3-15 ug/kg doses of CVT-510 given as either a singl...